Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL

    Primary Author / Presenter(s)

  • Paula Cramer, MD

    Faculty of Medicine and University Hospital Cologne
    Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
    Cologne, Germany

    • Co-Author(s)

  • EG

    Ellinor Görgen, Dr.

    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany
    Cologne, Nordrhein-Westfalen, Germany

  • LM

    Léa Mazot

    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany
    Cologne, Nordrhein-Westfalen, Germany

  • MS

    Miriam Schüler-Aparicio

    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany
    Cologne, Nordrhein-Westfalen, Germany

  • SR

    Sandra Robrecht

    Faculty of Medicine and University Hospital Cologne
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Cologne, Nordrhein-Westfalen, Germany

  • CP

    Christina Paulitschek

    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany
    Cologne, Nordrhein-Westfalen, Germany

  • AZ

    Aline Zey

    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany
    Cologne, Nordrhein-Westfalen, Germany

  • AA

    Antonia Albrecht, Dr.

    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany
    Cologne, Nordrhein-Westfalen, Germany

  • JB

    Julia Blau

    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany
    Cologne, Nordrhein-Westfalen, Germany

  • LJ

    Laura Jung

    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany
    Cologne, Nordrhein-Westfalen, Germany

  • SR

    Sophia Reidel, Dr.

    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany
    Cologne, Nordrhein-Westfalen, Germany

  • Othman Al-Sawaf, MD

    Faculty of Medicine
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Cologne, Germany

  • FB

    Francesc Bosch, MD, PhD

    Head, Dept of Hematology; Director, Experimental Hematology (VHIO); Professor
    Universtitat Autonoma Barcelona, Hospital Universitari Vall d'Hebron
    Barcelona, Catalonia, Spain

  • Cd

    Caspar da Cunha-Bang, MD, PhD

    Rigshospitalet, Copenhagen University Hospital, Department of Hematology
    Copenhagen, Hovedstaden, Denmark

  • Michael Doubek, MD, PhD

    Department head
    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic
    Brno, Jihomoravsky kraj, Czech Republic

  • EF

    Emadoldin Feyzi

    Department of Hematology, St. Olavs University Hospital, Trondheim, Norway
    Trondheim, Sor-Trondelag, Norway

  • AF

    Anna-Maria Fink

    Faculty of Medicine and University Hospital Cologne
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Cologne, Nordrhein-Westfalen, Germany

  • Paolo Ghia, MD, PhD

    Professor of Medical Oncology
    Università Vita Salute and IRCCS Ospedale San Raffaele
    Milano, Lombardia, Italy

  • MG

    Michael Gregor, MD

    Senior consultant
    Department of Hematology, Luzerner Kantonsspital
    Lucerne, Luzern, Switzerland

  • Romain Guieze, MD, PhD

    Professor of Hematology
    CHU Clermont-Ferrand
    Université Clermont Auvergne
    Clermont-Ferrand, France

  • KJ

    Krzysztof Jamroziak, MD, PhD

    Professor, Deputy Head of the Department of Hematology
    Medical University of Warsaw
    Warsaw, Poland

  • AJ

    Ann Janssens, MD

    Department of Hematology Campus Gasthuisberg, University Hospital, Leuven, Belgium
    Leuven, Vlaams-Brabant, Belgium

  • Arnon P. Kater, MD, PhD

    Vice Chair, Hematologist & Principal Scientist
    Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, and HOVON
    Amsterdam, Noord-Holland, Netherlands

  • SK

    Sabina Kersting, MD

    Department of Hematology, Haga Hospital, The Hague, Netherlands
    The Hague, Zuid-Holland, Netherlands

  • Petra Langerbeins, MD

    Faculty of Medicine and University Hospital Cologne
    Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
    Cologne, Germany

  • ML

    Mark-David Levin, MD

    Department of Internal Medicine, Albert Schweitzer Hospital
    Dordrecht, Zuid-Holland, Netherlands

  • VL

    Vesa Lindström, MD

    Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki
    Helsinki, Uusimaa, Finland

  • MM

    Mattias Mattsson, MD

    Department of Hematology, University Hospital
    Uppsala, Uppsala Lan, Sweden

  • Carsten U. Niemann, MD, PhD

    Associate Professor
    Rigshospitalet, Copenhagen University Hospital
    Copenhagen, Hovedstaden, Denmark

  • Anne Quinquenel, MD, PhD

    Dr
    CHU Reims
    Reims, France

  • MR

    Matthias Ritgen, MD

    University of Schleswig-Holstein, Campus Kiel
    Kiel, Schleswig-Holstein, Germany

  • Lydia Scarfò

    Assistant Professor
    Università Vita Salute and IRCCS Ospedale San Raffaele
    Milano, Lombardia, Italy

  • PS

    Philip Staber, MD, PhD

    Department of Medicine I, Division of Hematology and Hemostaseology, Medical University
    Vienna, Wien, Austria

  • Stephan Stilgenbauer, MD

    Professor of Medicine, Medical Director
    Division of CLL, Internal Medicine III, Ulm University
    Ulm, Baden-Wurttemberg, Germany

  • Tamar Tadmor, MD

    Associate Professor, Head of Hematology Unit
    Bnai Zion Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine
    Haifa, Israel

  • PT

    Patrick Thornton, MD

    Cancer Clinical Trials Unit, Beaumont Hospital
    Dublin, Ireland

  • Eugen Tausch, MD

    Treating Physician and Research Fellow
    Division of CLL, Department of Internal Medicine III, University Hospital Ulm
    Ulm, Germany

  • Loic Ysebaert, MD, PhD

    Professor of Hematology
    IUCT Oncopole
    Toulouse, Midi-Pyrenees, France

  • Kirsten Fischer

    Faculty of Medicine and University Hospital Cologne
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne and University of Cologne
    Cologne, Nordrhein-Westfalen, Germany

  • Barbara Eichhorst, MD

    Associate Professor, Consultant Hematologist
    Department I of Internal Medicine, University Hospital of Cologne
    Cologne, Germany

  • Michael Hallek, MD, PhD

    Principal Investigator, Director of Department I of Internal Medicine
    German CLL Study Group, University Hospital of Cologne
    Cologne, Germany